Physician profile
Terry A Grainger
NPI 1003854464
$10,011.16
in general payments reported to CMS, 2019-2025
36 companies · $2,367 in 2025
The $2,367 reported for 2025 was more than what 89% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $414 · 2021: $843 · 2022: $1,824 · 2023: $2,168 · 2024: $2,090 · 2025: $2,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,625.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,838.54 | 2021-2025 | |
| Abbott Laboratories | $1,120.46 | 2020-2025 | Aveir, Jot Dx, Gallant |
| E.R. Squibb & Sons, L.L.C. | $758.87 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $702.89 | 2020-2025 | Repatha, Repatha |
| Pfizer INC. | $595.10 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $539.09 | 2020-2025 | Lifevest |
| Boston Scientific Corporation | $531.87 | 2022-2025 | Cds - Mct/Cem Monitoring, Watchman Flx, Bodyguardian |
| Alnylam Pharmaceuticals INC. | $510.87 | 2022-2025 | Onpattro, Amvuttra |
| Philips North America LLC | $424.79 | 2022-2025 | (Ck4) Mcot, Event, Extended Holter |
| Merck Sharp & Dohme LLC | $406.46 | 2022-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $406.42 | 2020-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $331.16 | 2020-2024 | Xarelto |
| Heartflow, INC. | $320.73 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $265.10 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $210.28 | 2022-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $186.16 | 2020-2025 | Nexletol |
| Biotronik INC. | $154.44 | 2019 | |
| Scpharmaceuticals INC. | $88.23 | 2024 | |
| Axsome Therapeutics, INC. | $71.27 | 2024-2025 | Sunosi |
| Kiniksa Pharmaceuticals, LTD. | $61.79 | 2021-2023 | Arcalyst |
| Atricure, INC. | $52.89 | 2024-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Kiniksa Pharmaceuticals International, Plc | $46.49 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $42.59 | 2024 | |
| Cvrx, INC. | $40.82 | 2023 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $35.99 | 2020-2021 | |
| Cashflow Solutions, LLC | $35.71 | 2022-2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Jazz Pharmaceuticals INC. | $30.46 | 2024 | |
| Abiomed | $29.59 | 2024 | Impella |
| Amarin Pharma, INC. | $29.25 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $26.27 | 2024 | Opsumit, Uptravi |
| Daiichi Sankyo INC. | $24.93 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $22.65 | 2025 | Lumryz |
| Regeneron Healthcare Solutions, INC. | $19.41 | 2021 | |
| Lilly USA, LLC | $18.39 | 2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $16.39 | 2019 | |
| Chiesi USA, INC. | $14.81 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Grainger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.